Want to see AIMD full AI Analyst Report?
Top Page
Ainos
(NASDAQ:AIMD)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▲(7.14% Upside)
Action:Reiterated
Date:08/04/26
The score is driven primarily by very weak financial performance (minimal/declining revenue, large ongoing losses, negative operating/free cash flow) and increased balance-sheet risk from sharply reduced equity and higher leverage. Technicals add further pressure as the stock trades below key moving averages with negative MACD and sub-50 RSI. A small offset comes from the newly secured short-term unsecured credit facility supporting near-term liquidity, but it does not materially change the underlying profitability and cash-burn profile.
Positive Factors
Diversified therapeutics and diagnostics focus
A dual focus on exosome-based therapeutics and diagnostic sensor platforms provides multiple commercialization pathways and reduces dependence on a single product. Structurally, this diversification can smooth revenue timing and create cross-selling opportunities across pharma and diagnostics markets over 2–6 months and beyond.
Negative Factors
Declining revenue with large net losses
Sustained revenue decline and persistent large net losses indicate the core business is not scaling to cover costs. Over months this undermines the path to breakeven, increases reliance on external capital, and constrains resources for R&D or commercial launches, impairing strategic execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified therapeutics and diagnostics focus
A dual focus on exosome-based therapeutics and diagnostic sensor platforms provides multiple commercialization pathways and reduces dependence on a single product. Structurally, this diversification can smooth revenue timing and create cross-selling opportunities across pharma and diagnostics markets over 2–6 months and beyond.
Read all positive factors
Ainos (AIMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.34M
Dividend YieldN/A
Average Volume (3M)78.00K
Price to Earnings (P/E)―
Beta (1Y)2.21
Revenue Growth-82.95%
EPS Growth56.35%
CountryUS
Employees41
SectorTechnology
Sector Strength88
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.52
Shares Outstanding8,524,542
10 Day Avg. Volume93,591
30 Day Avg. Volume77,998
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.93
Price to Sales (P/S)56.41
P/FCF Ratio-1.51
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ainos Business Overview & Revenue Model
Company Description
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, ...
How the Company Makes Money
null...
Ainos Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
22
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.60K | 124.16K | 20.73K | 122.11K | 3.52M | 594.56K |
| Gross Profit | -4.76M | -4.68M | -31.87K | -253.73K | 1.41M | 410.38K |
| EBITDA | -8.96M | -9.28M | -9.44M | -8.77M | -9.14M | -1.83M |
| Net Income | -14.45M | -14.77M | -14.86M | -13.77M | -14.01M | -3.89M |
Balance Sheet | ||||||
| Total Assets | 19.56M | 20.87M | 28.82M | 31.84M | 37.11M | 40.82M |
| Cash, Cash Equivalents and Short-Term Investments | 1.42M | 417.35K | 3.89M | 1.89M | 1.85M | 1.75M |
| Total Debt | 11.00M | 11.00M | 12.00M | 5.96M | 1.27M | 3.62M |
| Total Liabilities | 16.28M | 13.31M | 13.30M | 7.39M | 2.48M | 30.63M |
| Stockholders Equity | 3.28M | 7.56M | 15.52M | 24.45M | 34.63M | 10.20M |
Cash Flow | ||||||
| Free Cash Flow | -4.49M | -4.65M | -5.83M | -4.79M | -3.67M | -1.39M |
| Operating Cash Flow | -4.47M | -4.61M | -5.81M | -4.69M | -3.04M | -1.25M |
| Investing Cash Flow | 23.12K | -2.22K | -125.29K | -101.53K | -630.18K | -180.52K |
| Financing Cash Flow | 4.70M | 1.01M | 8.03M | 4.92M | 3.85M | 3.15M |
Ainos Technical Analysis
Negative
1.40
Price Trends
1.86
Negative
1.74
Negative
1.97
Negative
Market Momentum
-0.14
Positive
38.78
Neutral
29.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIMD, the sentiment is Negative. The current price of 1.4 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 1.86, and below the 200-day MA of 1.97, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 38.78 is Neutral, neither overbought nor oversold. The STOCH value of 29.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIMD.
Ainos Risk Analysis
Ainos disclosed 52 risk factors in its most recent earnings report. Ainos reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Expansion into industrial and other non-healthcare environments may expose AI Nose to new and unforeseen risks. Q4, 2025
2.
We rely on the availability of licenses to third-party technology that may be difficult to replace or that may cause errors or delay implementation of our software and services should we not be able to continue or obtain a commercially reasonable license to such technology. Q4, 2025
3.
Our reliance on third-party components and cloud infrastructure could disrupt AI Nose operations, and any errors, disruption, performance problems, or failure in their or our operational infrastructure could adversely affect our business, financial condition, and results of operations. Q4, 2025
Ainos Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
53 Neutral | $11.16M | -1.41 | -67.85% | ― | ― | 63.33% | |
51 Neutral | $13.69M | -1.46 | -47.86% | ― | -93.71% | 23.89% | |
42 Neutral | $11.34M | -0.46 | -160.55% | ― | -82.95% | 56.35% | |
41 Neutral | $8.14M | -0.19 | -246.04% | ― | ― | 54.48% | |
40 Underperform | $4.26M | -0.11 | -767.07% | ― | ― | 22.10% |
* Technology Sector Average
AIMD
Ainos
1.42
-1.84
-56.44%
BLRX
Bioline RX Ltd Sponsored ADR
2.72
-1.17
-30.15%
SNGX
Soligenix
0.38
-2.82
-88.06%
CMMB
Chemomab Therapeutics
1.75
-2.17
-55.36%
FBLG
FibroBiologics, Inc.
0.87
-9.86
-91.91%
Ainos Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Ainos Secures Short-Term Unsecured Credit Facility in Taiwan
Positive
Jul 9, 2026
On July 3, 2026, Ainos, Inc. entered into a General Agreement for Omnibus Credit Lines with CTBC Bank Co., Ltd. in Taiwan, securing a short-term unsecured credit facility of NT$62,000,000, or about US$1.94 million, at an annual interest rate of 2....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.